Kymera Therapeutics (KYMR) stock price is $114.11, up 0.57% on the day, as of Oct 21, 2026. It has a market cap of $11.21Bn, and is classified in the Pharmaceuticals industry (Healthcare sector).
Enterprise Value
Margins
P/FCF
Key Stats
Market Cap11.21 Bn
P/E-37.42
P/S106.77
Div. Yield0.00
Revenue Growth (1y) (Qtr)466.40
Add ratio to table…
About
Kymera Therapeutics, Inc. is a clinical-stage biopharmaceutical company that develops oral small molecule medicines using its targeted protein degradation platform to treat immune inflammatory diseases. The company was founded to pursue a drug discovery approach that targets disease causing proteins previously considered undruggable by conventional small molecules. Its pipeline includes programs focused on STAT6, IRF5, IRAK4, and CDK2, each aimed at delivering oral therapies…
Kymera Therapeutics, Inc. is a clinical-stage biopharmaceutical company that develops oral small molecule medicines using its targeted protein degradation platform to treat immune inflammatory diseases. The company was founded to pursue a drug discovery approach that targets disease causing proteins previously considered undruggable by conventional small molecules. Its pipeline includes programs focused on STAT6, IRF5, IRAK4, and CDK2, each aimed at delivering oral therapies with potential biologics like efficacy. Kymera aims to advance at least one new molecular entity into clinical testing each year while building integrated capabilities for future commercialization. The company’s mission is to reinvent treatment of human disease by creating medicines that eliminate disease causing proteins rather than merely inhibiting their function. By harnessing the cell’s natural ubiquitin proteasome system, Kymera aims to achieve deeper and more durable target suppression. The company continues to invest in its discovery engine to identify additional high value targets that are amenable to its technology.
The company currently generates revenue through upfront payments, milestone payments, and royalties from collaboration agreements with pharmaceutical partners such as Sanofi and Gilead Sciences. As a pre revenue entity, Kymera has not yet recorded product sales and relies on these partnership financings to support research and development. Payments received include an upfront fee of one hundred fifty million dollars from the Sanofi collaboration and a forty million dollar upfront fee from the Gilead agreement. Additional potential earnings consist of development milestones, commercial milestones, and tiered royalties on future net sales. Milestone payments are triggered by predefined development, regulatory, or commercial achievements under the collaboration agreements. Royalty rates are structured as tiered percentages of net sales, offering upside potential if the partnered drugs reach the market. These financial arrangements allow Kymera to advance its programs while preserving capital for future internal initiatives.
Kymera Therapeutics is considered a leader in the targeted protein degradation field, competing with firms such as Arvinas, C4 Therapeutics, Nurix Therapeutics, and Foghorn Therapeutics. The company differentiates itself through a proprietary platform that enables degradation of transcription factors and other scaffolding proteins that are difficult to drug with traditional approaches. Its extensive patent estate covers E3 ligase ligand technologies and a range of degrader molecules, providing long term protection for its innovations. Kymera focuses on oral delivery of biologics like activity, seeking to improve patient convenience and broaden access compared to injectable alternatives. The firm’s scientific expertise in E3 ligase biology enables it to design molecules that are both potent and highly selective. This selectivity aims to reduce off target effects and improve safety profiles compared with less precise modalities. Its collaborative model with established pharmaceutical partners provides validation and access to broader development resources.
The company’s intended customers are patients suffering from immune inflammatory conditions such as atopic dermatitis, asthma, lupus, and rheumatoid arthritis, as well as the healthcare providers and payors that serve them. These conditions affect millions of people in the United States, Europe, and Japan, representing a significant unmet need for effective oral therapies. Kymera’s current collaborations involve Sanofi and Gilead Sciences, which fund and develop specific drug candidates targeting IRAK4 and CDK2 respectively. Successful commercialization would lead to distribution through pharmacies and healthcare providers, with payors assessing coverage and reimbursement for the new oral medicines. In addition to immune inflammatory diseases, Kymera explores oncology targets such as CDK2 through its collaboration with Gilead. The breadth of its pipeline reflects a strategy to apply the degradation platform across multiple therapeutic areas where high unmet need exists. By focusing on oral administration, Kymera seeks to address patient preferences for convenient dosing regimens.
Sector:HealthcareSector rationaleKymera Therapeutics is a clinical-stage biopharmaceutical company that develops small molecule medicines to treat immune inflammatory diseases and oncology targets. Its revenue is derived from collaboration agreements, milestone payments, and royalties from pharmaceutical partners like Sanofi and Gilead Sciences, which is characteristic of the Biotechnology and Pharmaceuticals industries within the Healthcare sector.Industry:PharmaceuticalsPharmaceuticalsPrimaryKymera Therapeutics develops oral small molecule medicines, such as those targeting STAT6, IRF5, IRAK4, and CDK2, which are branded prescription pharmaceuticals. The company's core business is the discovery and development of these small-molecule drugs to treat immune inflammatory diseases and oncology.Classified using BQ-MICSCIK: 0001815442
Bull & bear
Investment Thesis
▲ Bull case
The company highlighted its Phase IIb programs in atopic dermatitis and asthma but gave little emphasis to the broader potential of KT621 across the full spectrum of Type 2 mediated diseases such as chronic rhinositis with nasal polyps eosinophilic COPD and other mucosal disorders where IL 4 and IL 13 blockade has shown efficacy. The preclinical data shared in the call demonstrated robust activity in asthma models that exceeded dupilumab in several readouts suggesting a therapeutic effect that may extend beyond skin disease. Management noted the large untreated population of moderate to severe patients who rely on topical or inhaler therapies that do not address the underlying driver of disease indicating a sizable pool that could be captured by an oral agent with biologics like efficacy. If KT621 reproduces the biomarker improvements seen in the healthy volunteer study across multiple organ systems the addressable market could expand well beyond the current 20 billion dollar estimate and create a multi indication franchise that the market appears to be underpricing.
The partnership with Sanofi for the oral IRAK4 degrader KT485 and the collaboration with Gilead on the CDK2 molecular glue program were mentioned only briefly yet each carries the potential for significant near term milestones that could add non dilutive value to the balance sheet. Under the Sanofi agreement the company is eligible for nearly one billion dollars in total milestone payments including a payment upon dosing of the first healthy volunteer in the KT485 trial which is expected later this year. The Gilead deal provides an upfront payment of 40 million dollars and the opportunity to earn up to 750 million dollars in milestone payments including a 45 million dollar payment if Gilead exercises its option on the CDK2 program at the declaration of a mutually agreed upon development candidate. These potential cash inflows are not factored into the current cash guidance runway into 2029 and could provide additional funding to accelerate internal programs or offset future R&D spend thereby reducing perceived financial risk.
Management argued that an effective safe oral medicine could make it practical to intervene earlier in the disease course rather than waiting for significant progression or treatment failure a shift that would transform advanced therapy from a last resort for a small subset to a mainstream option for millions. This earlier use case is not captured in the current market sizing which assumes advanced systemic therapy is reserved for patients who have failed conventional therapies and could unlock a new wave of demand driven by preventive or early treatment strategies. The convenience of oral daily dosing combined with a safety profile comparable to injectable biologics could improve adherence and persistence thereby increasing the proportion of patients who remain on therapy long term. If KT621 demonstrates durable disease control in the Phase IIb studies the resulting change in prescribing behavior could expand the addressable market beyond the current estimate of 2 million treated patients and create a structural growth driver that is not reflected in today’s valuation.
The IRF5 degrader KT579 was presented as a genetically validated transcription factor with strong preclinical activity in lupus and rheumatoid arthritis models yet the call devoted relatively little time to discussing the upcoming proof of concept study in lupus patients that could validate the mechanism in humans. A successful demonstration of robust IRF5 degradation and downstream biomarker modulation in healthy volunteers followed by clinical activity in lupus would de risk the program and open the door to expansion into other autoimmune indications such as inflammatory bowel disease and Sjogrens syndrome where high unmet need remains. The company noted the strong genetic association between IRF5 and lupus and the lack of broad immunosuppression observed in preclinical toxicology studies suggesting a favorable safety margin that could differentiate KT579 from existing biologics that carry infection risks. Positive data from the lupus proof of concept could attract partnership interest or serve as a foundation for a standalone franchise thereby adding another growth vector that the market may be overlooking.
The company highlighted its Phase IIb programs in atopic dermatitis and asthma but gave little emphasis to the broader potential of KT621 across the full spectrum of Type 2 mediated diseases such as chronic rhinositis with nasal polyps eosinophilic COPD and other mucosal disorders where IL 4 and IL 13 blockade has shown efficacy. The preclinical data shared in the call demonstrated robust activity in asthma models that exceeded dupilumab in several readouts suggesting a therapeutic effect that may extend beyond skin disease. Management noted the large untreated population of moderate to severe patients who rely on topical or inhaler therapies that do not address the underlying driver of disease indicating a sizable pool that could be captured by an oral agent with biologics like efficacy. If KT621 reproduces the biomarker improvements seen in the healthy volunteer study across multiple organ systems the addressable market could expand well beyond the current 20 billion dollar estimate and create a multi indication franchise that the market appears to be underpricing.
The partnership with Sanofi for the oral IRAK4 degrader KT485 and the collaboration with Gilead on the CDK2 molecular glue program were mentioned only briefly yet each carries the potential for significant near term milestones that could add non dilutive value to the balance sheet. Under the Sanofi agreement the company is eligible for nearly one billion dollars in total milestone payments including a payment upon dosing of the first healthy volunteer in the KT485 trial which is expected later this year. The Gilead deal provides an upfront payment of 40 million dollars and the opportunity to earn up to 750 million dollars in milestone payments including a 45 million dollar payment if Gilead exercises its option on the CDK2 program at the declaration of a mutually agreed upon development candidate. These potential cash inflows are not factored into the current cash guidance runway into 2029 and could provide additional funding to accelerate internal programs or offset future R&D spend thereby reducing perceived financial risk.
Management argued that an effective safe oral medicine could make it practical to intervene earlier in the disease course rather than waiting for significant progression or treatment failure a shift that would transform advanced therapy from a last resort for a small subset to a mainstream option for millions. This earlier use case is not captured in the current market sizing which assumes advanced systemic therapy is reserved for patients who have failed conventional therapies and could unlock a new wave of demand driven by preventive or early treatment strategies. The convenience of oral daily dosing combined with a safety profile comparable to injectable biologics could improve adherence and persistence thereby increasing the proportion of patients who remain on therapy long term. If KT621 demonstrates durable disease control in the Phase IIb studies the resulting change in prescribing behavior could expand the addressable market beyond the current estimate of 2 million treated patients and create a structural growth driver that is not reflected in today’s valuation.
The IRF5 degrader KT579 was presented as a genetically validated transcription factor with strong preclinical activity in lupus and rheumatoid arthritis models yet the call devoted relatively little time to discussing the upcoming proof of concept study in lupus patients that could validate the mechanism in humans. A successful demonstration of robust IRF5 degradation and downstream biomarker modulation in healthy volunteers followed by clinical activity in lupus would de risk the program and open the door to expansion into other autoimmune indications such as inflammatory bowel disease and Sjogrens syndrome where high unmet need remains. The company noted the strong genetic association between IRF5 and lupus and the lack of broad immunosuppression observed in preclinical toxicology studies suggesting a favorable safety margin that could differentiate KT579 from existing biologics that carry infection risks. Positive data from the lupus proof of concept could attract partnership interest or serve as a foundation for a standalone franchise thereby adding another growth vector that the market may be overlooking.
While the KT621 data from the healthy volunteer and Phase Ib studies showed biomarker changes and clinical improvements that were in line with or numerically exceeded dupilumab at four weeks the company acknowledged that direct head to head comparisons have not been performed and that the true efficacy advantage remains uncertain until the Phase IIb readouts are available. The reliance on surrogate endpoints such as EASI and FeNO in early studies may overstate the clinical benefit especially given the modest sample sizes and short treatment duration in those trials. Management highlighted the enthusiasm from clinicians and patients for an oral option but did not address the possibility that the observed improvements could be driven by placebo effects or regression to the mean in a highly motivated early adopter population. If the Phase IIb trials fail to show a statistically significant separation from placebo the valuation premised on biologics like efficacy could be quickly undermined.
The company emphasized that IRF5 degradation does not cause broad immunosuppression citing mouse knockout models and preclinical toxicology studies that showed no increased susceptibility to infection yet it did not discuss potential off target effects on other interferon regulatory factors or the long term consequences of chronic IRF5 loss in human immune cells. The ex vivo stimulation assays used to assess functional impact in healthy volunteers are indirect measures and may not fully capture the complexity of cytokine networks in vivo leaving open the possibility of unforeseen safety signals when the drug is administered to patients with active autoimmune disease. Additionally the statement that missing a dose of KT621 does not lose pathway degradation while convenient does not eliminate the risk of adherence related fluctuations in drug exposure that could lead to suboptimal efficacy or safety concerns in real world use. Without long term safety data from extended exposure studies the risk of delayed adverse events remains a material uncertainty.
The transcript revealed that the company decided not to pursue the ITK target due to lymphoma risk signals yet it did not discuss the growing pipeline of oral small molecule inhibitors and degraders being developed by competitors that also aim to modulate the IL 4 IL 13 pathway or adjacent pathways in Type 2 diseases. Several other biotech firms have disclosed early stage programs targeting STAT6 or related kinases with oral formulations and some have already reported proof of concept data that could translate into clinical candidates ahead of Kymera’s timeline. The management narrative emphasized the first mover advantage of an oral degrader but did not provide a clear differentiation strategy beyond target engagement and convenience leaving open the risk that rivals could capture portions of the underserved patient base with comparable efficacy and better manufacturing or pricing profiles. If competitors achieve regulatory approval before KT621 the addressable market for Kymera’s product could be fragmented reducing its potential to dominate the oral Type 2 space.
Management stated that the Phase IIb studies will remain blinded until completion to protect integrity which prevents any interim look at efficacy or safety and could hide emerging problems such as lower than expected enrollment or a high placebo response that would diminish the observed treatment effect. The call gave limited detail on specific mitigation strategies for placebo beyond general statements about site selection and investigator training leaving investors to wonder whether the measures are sufficient to overcome the known challenge of high placebo rates in atopic dermatitis and asthma trials. Additionally the regulatory strategy relies on completing Phase II then holding an FDA meeting before starting Phase III yet the company did not address potential delays that could arise from requests for additional preclinical data or manufacturing information which could push the timeline for pivotal data beyond the mid 2027 and late 2027 guidance. Any extension of the development timeline would increase cash burn erode the runway advantage and shift the risk reward balance toward the downside.
While the KT621 data from the healthy volunteer and Phase Ib studies showed biomarker changes and clinical improvements that were in line with or numerically exceeded dupilumab at four weeks the company acknowledged that direct head to head comparisons have not been performed and that the true efficacy advantage remains uncertain until the Phase IIb readouts are available. The reliance on surrogate endpoints such as EASI and FeNO in early studies may overstate the clinical benefit especially given the modest sample sizes and short treatment duration in those trials. Management highlighted the enthusiasm from clinicians and patients for an oral option but did not address the possibility that the observed improvements could be driven by placebo effects or regression to the mean in a highly motivated early adopter population. If the Phase IIb trials fail to show a statistically significant separation from placebo the valuation premised on biologics like efficacy could be quickly undermined.
The company emphasized that IRF5 degradation does not cause broad immunosuppression citing mouse knockout models and preclinical toxicology studies that showed no increased susceptibility to infection yet it did not discuss potential off target effects on other interferon regulatory factors or the long term consequences of chronic IRF5 loss in human immune cells. The ex vivo stimulation assays used to assess functional impact in healthy volunteers are indirect measures and may not fully capture the complexity of cytokine networks in vivo leaving open the possibility of unforeseen safety signals when the drug is administered to patients with active autoimmune disease. Additionally the statement that missing a dose of KT621 does not lose pathway degradation while convenient does not eliminate the risk of adherence related fluctuations in drug exposure that could lead to suboptimal efficacy or safety concerns in real world use. Without long term safety data from extended exposure studies the risk of delayed adverse events remains a material uncertainty.
The transcript revealed that the company decided not to pursue the ITK target due to lymphoma risk signals yet it did not discuss the growing pipeline of oral small molecule inhibitors and degraders being developed by competitors that also aim to modulate the IL 4 IL 13 pathway or adjacent pathways in Type 2 diseases. Several other biotech firms have disclosed early stage programs targeting STAT6 or related kinases with oral formulations and some have already reported proof of concept data that could translate into clinical candidates ahead of Kymera’s timeline. The management narrative emphasized the first mover advantage of an oral degrader but did not provide a clear differentiation strategy beyond target engagement and convenience leaving open the risk that rivals could capture portions of the underserved patient base with comparable efficacy and better manufacturing or pricing profiles. If competitors achieve regulatory approval before KT621 the addressable market for Kymera’s product could be fragmented reducing its potential to dominate the oral Type 2 space.
Management stated that the Phase IIb studies will remain blinded until completion to protect integrity which prevents any interim look at efficacy or safety and could hide emerging problems such as lower than expected enrollment or a high placebo response that would diminish the observed treatment effect. The call gave limited detail on specific mitigation strategies for placebo beyond general statements about site selection and investigator training leaving investors to wonder whether the measures are sufficient to overcome the known challenge of high placebo rates in atopic dermatitis and asthma trials. Additionally the regulatory strategy relies on completing Phase II then holding an FDA meeting before starting Phase III yet the company did not address potential delays that could arise from requests for additional preclinical data or manufacturing information which could push the timeline for pivotal data beyond the mid 2027 and late 2027 guidance. Any extension of the development timeline would increase cash burn erode the runway advantage and shift the risk reward balance toward the downside.